...101 for a new indication: treatment-resistant depression (TRD). Under the original 2004 deal, the biotech's Evotec Neurosciences GmbH...
...deal was orchestrated by John Kemp, now Evotec's chief R&D officer and then CEO of Evotec Neurosciences...

...a pure-play CNS company. The first signal of the transition was the reacquisition of its Evotec Neurosciences...
...the reduction of the company's reliance on its service businesses. At the time of the Evotec Neurosciences...

...of more than E1 million from Takeda under a 2003 deal in which EVT subsidiary Evotec Neurosciences...

...received an undisclosed milestone payment from Takeda under a 2003 deal in which EVT subsidiary Evotec Neurosciences...

...ASX:BNO; BMICY) Australia Neurofit France E1.3M ($1.7M) in cash & stock Mar Evotec (FSE:EVT) Germany Evotec Neurosciences...

...is scheduled for July 27. Evotec's buy-in When Evotec (FSE:EVT) re-integrated its drug discovery subsidiary Evotec Neurosciences...
...EVT raised a28.4 million ($34.4 million) through the sale of 10 million shares at a2.72. Evotec Neurosciences...

...stronger syndicate," he said. A very different example is the re-acquisition of Evotec OAI AG's Evotec Neurosciences...

...Marubeni Ablynx Belgium $30.3 Alta Partners; Abingworth Management; GIMV; Biotech Fund Flanders; Sofinnova Partners; Gilde Evotec Neurosciences...

...EVT's subsidiary, Evotec Neurosciences GmbH, in-licensed an undisclosed compound from an undisclosed company. The compound has completed a...

...which Evotec Neurosciences investors will get about 14.3 million newly issued EVT shares. The transaction values Evotec Neurosciences...
...an investor in Evotec Neurosciences. "For a small company that is advancing at a pace like Evotec Neurosciences...
...to AD, and Evotec Neurosciences will validate selected target candidates for small molecule development. In exchange, Evotec Neurosciences...